Research - Grant Funded Research
Current Research Projects:
The UTMC Epilepsy Center is involved in several major clinical trials testing new therapies. A number of these studies are currently closed to patient enrollment, but there are many studies that are still looking for participants. These studies include:
Epilepsy:
- A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study To Evaluate The Efficacy And Safely Of Adjunctive Perampanel In Primary Generalized Tonic-Clonic Seizures. (E2007-G000-332)
- A Prospective, Multinational, Open-Label, Single Arm, Explorative Study To Evaluate The Tolerability And Efficacy Of Lacosamide When Added To Levetiracetam With Withdrawal Of The Concomitant Sodium Channel Blocking Antiepileptic Drug In Subjects With Uncontrolled Partial-Onset Seizures (SP0980)
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study To Evaluate The Efficacy And Safety Of Brivaracetam In Subjects With Partial Onset Seizures. (NO1358)* (*Patients who complete N01358 study will be potentially eligible to enter an open-label, long term follow-up study with BRV)
- A Phase 2, Multicenter, Double-Blind, Randomized, Adjunctive Placebo-Controlled Trial to Evaluate the Efficacy and Safety of YKP3089 in Subjects with Treatment Resistant Partial Onset Seizures; Protocol # YKP3089C013; Sponsor: SK Life Sciences
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Clinical Trail; BIA2093-304; Sponsor: Sunovian
- LONG TERM ESLICARBAZEPINE ACETATE MONOTHERAPY EXTENSION STUDY; Protocol # 093- 050; SPONSOR: Sunovion, Inc. (*This is the second, extension phase of the double blind eslicarbazepine acetate monotherapy study 093-045 that we completed)
- A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures; Protocol# SP904; Sponsor: UCB
Multiple Sclerosis:
- A single arm, open-label, multicenter study evaluating the long-term safety, tolerability and efficacy of 0.5 mg fingolimod (fty720) administered orally once daily in patients with multiple sclerosis; Sponsored by Novartis Pharmaceuticals
- A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of fingolimod 0.25 mg and 0.5 mg administered orally once daily with glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis; Sponsored by Novartis Pharmaceuticals
- A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta; Sponsored by Sanofi
Stroke:
- Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial; In collaboration with the University of California, San Francisco; supported by the National Institute of Neurological Disorders and Stroke (NINDS)